• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Dexcom beats the Street with Q2 results

August 1, 2018 By Sarah Faulkner

DexcomDexcom (NSDQ:DXCM) topped sales and earnings expectations on Wall Street today with its second-quarter financial results.

The San Diego, Calif.-based company posted profits of $30.2 million, or 34¢ per share, on sales of $242.5 million for the three months ended June 30, representing a whopping 941% increase in profits and a 42% increase in sales compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -10¢, ahead of the -18¢ consensus on The Street, where analysts were looking for sales of $205.7 million.

“Q2 was a fantastic quarter for Dexcom and demonstrates that CGM adoption is increasing significantly,” president & CEO Kevin Sayer said in prepared remarks. “This performance was particularly notable considering we only began launching our revolutionary G6 platform late in the quarter, and we are pleased to be able to raise our full-year growth outlook.”

Dexcom said it expects to post sales of $925 million for the full year, up from the prior range of $850 million to $860 million.

DXCM shares were trading at $107.00 apiece today after close, up 12%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: DexCom Inc.

IN CASE YOU MISSED IT

  • Senseonics stock is up as it sticks by revenue guidance
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS